



2614

**CERTIFICATE OF MAILING PURSUANT TO 37 C.F.R. §1.8**

I hereby certify that this correspondence, pursuant to 37 C.F.R. §1.8, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on:

DATE: Aug. 26, 2005 BY: [Signature]

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

PATENT

Applicant(s):	Kei TASHIRO, et al.	Docket No.:	29288.5600
U.S. Serial No.:	10/089,776	U.S. Filing Date:	June 21, 2002
Group Art Unit:	1641	Confirmation No.:	2614
TITLE:	HIGH SENSITIVITY IMMUNOASSAY METHOD	Examiner:	Shafiqul Haq

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner of Patents  
PO Box 1450  
Alexandria, VA 22313

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, the reference or references listed and identified on the attached PTO/SB08 based form are being submitted herewith for consideration by the Examiner. A copy of the listed references are enclosed.

The reference or references are being cited only in the interest of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

This Information Disclosure Statement (IDS) is being filed under 37 C.F.R. §1.97(c) as each item of information contained in this disclosure is being filed before the mailing date, if


any, of a final action under § 1.113, a notice of allowance under § 1.113, or an action that otherwise closes prosecution in the application, and therefore no fee is required. The enclosed references are also being submitted under 37 C.F.R. §1.97(e)(2) as each reference cited herein was not cited in any communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the IDS was known to any individual as designated by 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. If Applicant has overlooked any fees, the Commissioner is hereby authorized to debit Deposit Account No. 19-2814 for the same.

**A duplicate copy of this Information Disclosure Statement is enclosed for this purpose.**

If there are any questions concerning this IDS, the Examiner is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the United States Patent and Trademark Office is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 19-2814.

Respectfully submitted,

Date: August 26, 2005

By   
Robert A. Iussa  
Reg. No. 51,337

**SNELL & WILMER L.L.P.**  
One Arizona Center  
400 East Van Buren  
Phoenix, AZ 85004-0001  
P: (602) 382-6226  
F: (602) 382-6070



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 14

*(Use as many sheets as necessary)*

Sheet

1

of

1

**Complete if Known**

Application Number

10/089,776

Filing Date

June 21, 2002

**First Named Inventor**

Kei TASHIRO

## Art Unit

1641

Examiner Name

**Shafiqul Haq**

Attorney Docket Number

**29288.5600**

Examiner  
Initials\*Cite  
No. 1

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

 $T^2$ 

EDWARD J. LEONARD, "Plasma Chemokine and Chemokine--Autoantibody Complexes in Health and Disease," Copyright 1996 by Academic Press, Inc.

Examiner  
Signature

Date \_\_\_\_\_

**Considered**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

***If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.***